Cel On European scale, out of an estimated 3.45 million new cases of cancer, the most common sites are female breast, colon, lung and prostate. These four cancers represent half of the overall burden of cancer in Europe, with an economic impact estimated over 125 billion euros. With a potential of global implementation, Trivisio's ARVisS system range will provide more accessible, yet strongly improved, accuracy, completeness and time efficiency in the surgical management of the common, high incidence, malignant cancer tissues. A novel approach is proposed implementing advanced microscopy, in combination with real-time fluorescence and 3D, in-sight image guidance by pre- and intraoperative diagnostic data. Bringing these three main benefits in a straightforward, easy-to-use fashion to the practicing surgeons, the proposed medical device has the potential to bridge the current gap between traditional surgical glass loupes with external information and high standard microscopy devices. Realization of this challenge is possible when Trivisio’s leading know-how and available state-of-the-art technologies, such as augmented reality and optical see-through head-mounted displays, are integrated in a simplified resection tool for healthcare. Higher success rates, time efficiency and subsequent financial cost of more common surgical interventions can then be achieved at only 25% of the current investment budget. Higher survival chances are aimed at by the decrease of post-operative side effects and a reduced cancer recurrence, leading to a lowering of the financial pressure on both medical institutions and national health care systems. Dziedzina nauki natural sciencesphysical sciencesopticsmicroscopymedical and health sciencesclinical medicineoncologybreast cancermedical and health sciencesclinical medicinesurgerysurgical proceduresengineering and technologymaterials engineeringnatural sciencescomputer and information sciencessoftwaresoftware applicationssimulation software Program(-y) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Temat(-y) PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Zaproszenie do składania wniosków H2020-SMEInst-2014-2015 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-1-2015 System finansowania SME-1 - SME instrument phase 1 Koordynator TRIVISIO PROTOTYPING GMBH Wkład UE netto € 50 000,00 Adres HERZOGENBUSCHER STRASSE 14 54292 TRIER Niemcy Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Region Rheinland-Pfalz Trier Trier, Kreisfreie Stadt Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 71 429,00
